← Browse by Condition
Medical Condition

hematopoietic and lymphoid cell neoplasm

Total Trials
3
Recruiting Now
3
Trial Phases
EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for hematopoietic and lymphoid cell neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hematopoietic and lymphoid cell neoplasm Clinical Trials

How many clinical trials are currently recruiting for hematopoietic and lymphoid cell neoplasm?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for hematopoietic and lymphoid cell neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hematopoietic and lymphoid cell neoplasm?
hematopoietic and lymphoid cell neoplasm research spans Phase 1 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hematopoietic and lymphoid cell neoplasm clinical trial?
Eligibility criteria for hematopoietic and lymphoid cell neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Top Sponsors
M.D. Anderson Cancer Center 3 trials

Recruiting Clinical Trials

NCT04744116 EARLY_Phase 1
Recruiting
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Enrollment
24 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06184321 EARLY_Phase 1
Recruiting
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Enrollment
30 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT02464696
Recruiting
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
Enrollment
256 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

malignant solid neoplasm (2) steroid refractory graft versus host disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology